Low-Dose Versus Standard-Dose Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Multicentre, Non-Inferiority, Double-Blind, Randomised, Controlled Trial

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP.
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effective in reducing the incidence of PEP when administered rectally before ERCP. The standard dose recommended by guidelines is 100mg, which has been associated with a significant reduction in PEP rates. However, higher doses of NSAIDs can increase the risk of adverse events, including gastrointestinal bleeding and renal impairment. Therefore, there is a need to determine whether a lower dose can provide similar benefits without increasing these risks.
This multicenter, non-inferiority, double-blind, randomized controlled trial will be conducted in China. Participants will be adults aged 18 or older scheduled for ERCP. They will be randomly assigned in a 1:1 ratio to either the low-dose (50mg) or standard-dose (100mg) indomethacin group. The intervention will be administered rectally 30 minutes before the ERCP procedure. The study will follow a double-blind design, ensuring that both patients and investigators are unaware of the treatment allocation.
The results of this trial could significantly influence clinical practice by providing evidence on the effectiveness of a lower dose of indomethacin in preventing PEP. This could lead to a reduction in the risk of adverse events associated with higher doses and potentially decrease healthcare costs without compromising patient safety. By optimizing the dosing of indomethacin, this study aims to improve the safety and cost-effectiveness of ERCP procedures.

Start Date01 Sep 2025

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+9]

NCT07035808

/ Not yet recruitingPhase 2IIT

Efficacy and Safety of Iparomlimab and Tuvonralimab(QL1706) Combined With Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy for High-risk Locally Advanced Cervical Cancer：a Single Arm, Phase II Multicenter Clinical Study

This study is a single arm, phase II multicenter clinical trial to evaluate the efficacy and safety of the combination therapy of Iparomlimab and Tuvonralimab(QL1706) and chemotherapy ± bevacizumab induction therapy followed by concurrent chemoradiotherapy in patients with locally advanced cervical cancer at high risk of IVA stage and/or giant cervical tumors and/or giant metastatic lymph nodes and/or multiple metastatic lymph nodes.
The enrolled patients first receive 2 cycles of combined drug induction therapy: paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706, every 3 weeks for 2 cycles; After induction therapy, synchronous radiotherapy and chemotherapy combined with immunotherapy: extracorporeal irradiation+post loading radiotherapy+synchronous chemotherapy+immunotherapy. During radiotherapy, single agent cisplatin/carboplatin treatment for 5 courses per week+QL1706 treatment every 3 weeks for 3 courses; After the end of radiotherapy and chemotherapy, immune maintenance therapy will be administered for six months: treatment with QL1706 every 3 weeks for 9 courses, followed by a follow-up period until the end of radiotherapy for 2 years or death.

Start Date01 Jul 2025

Sponsor / Collaborator

Zhejiang Cancer Hospital

[+8]

NCT07030881

/ Not yet recruitingNot ApplicableIIT

Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy: A Multicenter Randomized Controlled Trial

This study evaluates whether adding a spacer device to triple inhaled therapy (ICS/LABA/LAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High-risk is defined as ≥1 hospitalization or ≥2 moderate exacerbations in the past 12 months.
Despite receiving maximum inhaled treatment, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects.
In this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved face-mask spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.

Start Date20 Jun 2025

Sponsor / Collaborator

Ningbo University

100 Clinical Results associated with Ningbo University

0 Patents (Medical) associated with Ningbo University

22,159

Literatures (Medical) associated with Ningbo University

01 Feb 2026·FOOD HYDROCOLLOIDS

Synergistic enhancement of gelation and protein interactions in low-salt shrimp gels by static magnetic field and microcrystalline cellulose

Author: Wei, Huamao ; Ou, Changrong ; Yuan, Chunhong ; Liu, Siyang ; Zhang, Tong ; Yang, Yingying ; Yang, Wenge ; Li, Chunyu

With the purpose of developing low-salt shrimp gel products, the present study explored the influence of the low-temperature static magnetic field (LT-SMF) pre-gelation process combined with the additions of microcrystalline cellulose (MCC) on the gel quality enhancement and its mechanism.LT-SMF process was used to treat the shrimp gels, and different proportions of MCC were added to evaluate the gels via textural properties, drip loss and water distribution, protein properties, and microstructure with mol. docking method.The results suggested that an MCC addition of 0.6 % significantly enhanced the hardness, chewiness, and springiness of the shrimp gels, reduced drip loss, and improved water holding capacity.SDS-PAGE analyses and FTIR anal. indicated that the combined LT-SMF and MCC treatment synergistically promoted the formation of β-sheet structures in proteins and facilitated the crosslinking of the myosin heavy chain (MHC), thereby leading the stability of the gel network enhanced.The microstructural results indicated that the collaborative-treated gel network became more uniform and denser.Mol. docking simulations further revealed the stable binding mechanism between biosaccharides in MCC and MHC in shrimp.This study provides a new insight into the development of low-salt shrimp gel products and offers significant theor. and practical value.

01 Jan 2026·TALANTA

Robust removal of thallium(I) from water with nano-MnO2 implanted zwitterionic porous hydrogel

Article

Author: Wu, Hongjie ; Jia, Xiaoyu ; Gong, Dirong

The uncontrolled disposal of Tl(I) waste comes at a significant economic and environmental cost because of the acute toxicity and high mobility. To resolve the aggregation problem for most reported MnO₂ based adsorbent materials which significantly affected the adsorption efficiency, porous zwitterionic ammonium propyl sulfonate (zw) polyacrylamide hydrogel (PAAm) has been fabricated to disperse nano-MnO₂ as a support. The developed nano-MnO₂@PAAm-zw exhibited a specific surface area of 5.06 m²/g and a pore diameter of 23.8 nm. particularly amenable to removal of Tl(I) for environmental remediation. The factors, including adsorbent MnO₂ incorporation, feeding amount, adsorption time, pH of the solution, Tl(I) initial concentration and existence of competing cations that governing the adsorption performances were fully elucidated. The maximal removal capacity Q_e reaches up to 336.5 mg (Tl) g^-1(MnO₂) with 99.92 % elimination efficiency and a low residue of 4.5 μg L^-1. The materials exhibit an astonishing robustness against nature matrix and high concentration of cations with adsorption capacity being 928.6-41.43 times larger than various competing counterparts for lab-made and mineral samples, representing the state-of-the-art level of adsorbents. The adsorbent can be regenerated at least five times retaining 86.0 % of original efficiency. A novel concerted mechanistic pathway of retention mainly associated with re-dox reaction is possible. These features offer great potentials for selective and deep elimination of total thallium in water samples.

01 Jan 2026·TALANTA

Streamlining diagnosis of bloodstream infections with high-throughput microfluidic isolation and aptamer-based detection strategies

Article

Author: Wang, Yanlin ; Wu, Chaoqian ; Yu, Shaoning ; Gao, Wenjing

Bloodstream infections have high morbidity and mortality rates. Currently, the gold standard for diagnosing bloodstream infections involves re-culturing bacteria from positive culture bottles for mass spectrometry and drug resistance analysis. However, this process incurs a delay of at least a day, which can lead to a 7.6 % increase in the hourly mortality rate. Therefore, accelerating the identification of bacterial species and determining drug resistance is critical. Here, we present a new high-throughput Dean flow fractionation (DFF^HT) spiral chip to efficiently sort pathogenic bacteria from positive blood culture bottles, achieving an efficiency >80 %. Pathogens enriched in DFF^HT devices are directly identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), followed by the determination of drug-resistance by aptamer fluorescence, thereby eliminating the need for plate recultivation. Three high probability drug-resistant bacteria (carbapenem-resistant Acinetobacter baumannii [CRAB], carbapenem-resistant Pseudomonas aeruginosa [CRPA], and methicillin-resistant Staphylococcus aureus [MRSA]) were successfully identified directly from positive blood culture bottles. This combination of DFF^HT microfluidic bacterial isolation and aptamer-based detection of drug resistance can be completed within 1 h with a 2 mL sample from a positive blood bottle, which is helpful for doctors choosing the right antibiotic in time to treat the patient effectively.

News (Medical) associated with Ningbo University

23 Apr 2025

·www.prnewswire.com

A Breakthrough in Brain Surgery Monitoring: Guarding Lives with Raytron's Thermal Imaging Technology

YANTAI, China, April 23, 2025 /PRNewswire/ -- In high-stakes neurosurgery, gaining real-time insights into cerebral blood flow is vital yet challenging. Conventional indocyanine green (ICG) fluorescence imaging relies on contrast agents and offers limited repeatability. Now, infrared thermography cameras promise a non-contact, contrast-free, radiation-free, and non-invasive diagnostic imaging alternative, delivering continuous monitoring that enhances surgical precision and patient safety. How Infrared Thermal Imaging Empowers Medical Diagnostics Thermal imaging cameras convert subtle temperature variations from cerebral blood circulation into high-resolution thermal maps, enabling surgeons to "see" vascular flow invisible to the naked eye. This non-invasive thermal imaging technology integrates seamlessly into neurosurgical workflow, such as cerebrovascular bypass, offering continuous intraoperative monitoring without interruption. Raytron's Thermographic Imaging Camera for Clinical Application in Neurosurgery Raytron, a prominent global provider of infrared thermal imaging solutions, has developed an innovative thermal camera for medical use. In 2023, a surgical team led by Dr. Lin Jinghui at the First Affiliated Hospital of Ningbo University—a top-tier public hospital in China—deployed Raytron's proprietary ATR1280 thermal imaging camera during life-saving bypass operations for patients with moyamoya disease, a rare cerebrovascular disorder. The team conducted intraoperative infrared imaging on 21 adult patients undergoing STA-MCA (superficial temporal artery to middle cerebral artery) bypass surgery and identified several key advantages over conventional methods: Real-time, high-resolution thermal imaging camera for research Clearer visualization of anastomotic blood flow Seamless integration into the surgical workflow Greater quantitative accuracy in cerebral blood flow monitoring These benefits may support more informed decision-making and contribute to improved patient outcomes, marking a promising development in thermographic neurosurgical imaging. Raytron's Global Vision in Infrared Thermal Imaging: Raytron is a leading high-tech enterprise dedicated to the research and development of ASICs, MEMS sensors, and AI algorithms. With a portfolio of 1,200 patents and an R&D workforce comprising 48% of its over 3,000 employees, Raytron delivers advanced thermal imaging solutions in medical diagnostics, emergency response and 10 other industry sectors worldwide. Committed to advancing intelligent sensing technology solutions, Raytron aims to create incremental value for customers with technological advancements and help people discover the beauty of the world from more dimensions. For Further Information Contact us for medical-use thermal imaging solutions: Raytron Marketing Department E-mail: [email protected] Website: SOURCE Raytron Technology Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Ningbo University

100 Translational Medicine associated with Ningbo University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Flavokawain A ( CDT1 )	Acute Myeloid Leukemia More	Preclinical
BAY 61-3606 ( MAP4K2 x RB1 x Syk )	Acute Myeloid Leukemia More	Preclinical
AM-04(Ningbo University)	Bacterial Infections More	Preclinical
Cucurbitacin IIb	Colitis More	Preclinical
CN119119256 ( E-protein )Patent Mining	Nervous System Diseases More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis